Upon joining the trial, you will be randomly assigned to one of the treatment groups. This means you will either receive the medication or be part of the active monitoring group. The assignment is random to ensure fairness and accuracy in the trial results.

If assigned to the durvalumab group, you will receive a medication called durvalumab. This is given as an infusion, which means it is administered directly into your bloodstream through a vein. The dosage is 50 mg/mL and the frequency and duration will be explained by the medical team.

If assigned to the combination treatment group, you will receive both durvalumab and tremelimumab. These are also given as infusions. Durvalumab is administered at a dosage of 50 mg/mL and tremelimumab at 20 mg/mL. The medical team will provide details on the frequency and duration of these infusions.

If assigned to the active monitoring group, you will not receive the trial medications. Instead, your health will be closely monitored through regular check-ups and tests to observe any changes in your condition.

Throughout the trial, you will have regular follow-up appointments. These appointments are important to monitor your health, manage any side effects, and assess the effectiveness of the treatment. The schedule for these follow-ups will be provided by the medical team.

At the end of your participation in the trial, you will have a final assessment. This will include a review of your health status and any changes observed during the trial. The medical team will discuss the next steps and any further treatment options if necessary.